Composition of the Nomination Committee of Orion Corporation

ORION CORPORATION STOCK EXCHANGE RELEASE 21 OCTOBER 2020 at 6.40 p.m. EESTComposition of the Nomination Committee of Orion CorporationThe Board of Directors of Orion Corporation has elected the following persons to the Nomination Committee of the company:Annika EkmanPetteri KarttunenTimo MaasiltaMikael Silvennoinen
Heikki WesterlundJukka YlppöHeikki Westerlund was elected Chairman of the Committee.
Orion Corporation
Contact person:
Timo Lappalainen, President and CEO
tel. +358 10 426 3692Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
Homepage: www.orion.fi
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion’s pharmaceutical R&D are neurological disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion’s net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion’s A and B shares are listed on Nasdaq Helsinki.